NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

MEASuRE: Metreleptin Effectiveness And Safety Registry

RecruitingN/A

Sponsor: Chiesi Farmaceutici S.p.A.

Conditions: Generalised Lipodystrophy, Partial Lipodystrophy

Interventions: Metreleptin

Countries: United States, France, Germany, Italy, United Kingdom

The study is a post-authorization, prospective, voluntary registry of patients treated with commercial metreleptin including, but not limited to, patients in the US and EEA.

Eligibility overview

Sex: ALL

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

* Patients treated with metreleptin through commercial supply at the time or before enrolment into registry
* Patients who provide a written consent
* Patient coming off metreleptin clinical studies and continuing or restarting treatment with metreleptin through commercial supply

Exclusion Criteria:

• Patients currently treated with an investigational agent as part of a clinical trial

Locations (28)

Birmingham, Alabama, United States
Duarte, California, United States
Atlanta, Georgia, United States
Chicago, Illinois, United States
Kansas City, Kansas, United States
New Orleans, Louisiana, United States
New Orleans, Louisiana, United States
Bethesda, Maryland, United States
Ann Arbor, Michigan, United States
Detroit, Michigan, United States
Staten Island, New York, United States
Columbus, Ohio, United States
Philadelphia, Pennsylvania, United States
Philadelphia, Pennsylvania, United States
Dallas, Texas, United States
Seattle, Washington, United States
Lille, Nord, France
Paris, Paris, France, France
Paris, Paris, France
Ulm, Baden-Wurttemberg, Germany
Hanover, Lower Saxony, Germany
Münster, North Rhine-Westphalia, Germany
Leipzig, Saxony, Germany
Bologna, Bologna, Italy
Pisa, Pisa, Italy
Roma, Roma, Italy
Novara, Verceilli, Italy
Cambridge, Cambridge, United Kingdom